You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Expanded access for Zolgensma following final NICE guidance

The National Institute for Health and Care Excellence (NICE) has published its final guidance on Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma.